From BrainScope’s pediatric traumatic brain injury assessment device to EOS Imaging releasing new surgery planning software, here are seven medtech stories we missed this week but thought were still worth a mention. 1. BrainScope to develop pediatric traumatic brain injury assessment device BrainScope announced in a Sept. 7 press release that it will immediately start creating […]
Bonesupport
Bonesupport closes $57m IPO
BoneSupport said last week it closed its initial public offering, raising a total of approximately $57.1 million (SEK 500 million), not including an over-allotment option. The Swedish company, which is developing the Cerament G injectable antibiotic-eluting bone graft substitute, said it floated approximately 17.2 million new shares at $3.40 per share (SEK 29) in the […]
BoneSupport readies $62m IPO
BoneSupport said this week that it’s planning to float an initial public offering that would fetch roughly $62 million at the midpoint, not including an over-allotment option. The Swedish company, which is developing the Cerament G injectable antibiotic-eluting bone graft substitute, said it plans to offer more than 18.5 million shares at $3.13 to $3.59 apiece […]
BoneSupport launches trial of antibiotic-eluting bone graft
BoneSupport said today that the 1st patient has been enrolled in the pivotal investigational device exemption trial for its injectable antibiotic-eluting bone graft substitute. The company’s Fortify trial plans to evaluate Cerament G’s ability to improve the traditional management of patients with open factures of the tibial diaphysis. The trial is slated to enroll up […]
Organovo CEO Murphy steps away, Crouch steps up | Personnel Moves | April 14, 2017
Organovo (PINK:ONVO) said earlier this week that Taylor Crouch has been appointed as CEO, replacing Keith Murphy who is stepping away from the company. The changes are slated to go into effect on April 21. Prior to being tapped for the corner office, Crouch operated as CEO of investigative clinical research company eStudySite, the San Diego, […]
7 medtech stories we missed this week: March 24, 2017
From companies receiving CE marking to other companies adjusting their distribution deals, here are 7 medtech stories we missed this week but thought were still worth mentioning. 1. Viveve Medical closes public offering Viveve Medical announced that it closed its underwritten public offering of 8,625,00 shares of its common stock, according to a March 22 […]
Zimmer Biomet elevates Delp to Americas prez | Personnel Moves | January 22, 2017
Zimmer Biomet (NYSE:ZBH) said this week it tapped Robert Delp as its new Americas president, lifting him from his previous position as VP of US sales. Delp will replace former Americas prez Stuart Kleopfer, who is retiring from the position but will continue to work with the company while Delp transitions into his position. The shift […]
Bonesupport raises $37m to support Cerament platform
Bonesupport said today it raised $37 million in anew round of equity and debt financing, with funds slated to support its Cerament platform of products. The oversubscribed equity round was led by Tellacq AB and joined by existing shareholders, including HealthCap, Lundbeckfond Ventures, Industrifonden, AP3 and Carl Westin, with the debt round being supported by Kreos […]
Bonesupport touts high infection eradication rate in prospective trial
Bonesupport today released data from the prospective trial of its Cerament G injectable antibiotic-eluting bone substitute, touting a 96% infection eradication rate in patients treated with the substitute. Data from the study was published in The Bone and Joint Journal, the company said. Cerament G is an osteoconductive, ceramic substance designed to promote bone healing […]
Bonesupport wins FDA nod for Cerament G trial
Bonesupport said it won an investigational device exemption for the Fortify clinical trial of its next-generation Cerament G injectable antibiotic-eluting bone substitute. Cerament G product is an osteoconductive, ceramic substance designed to promote bone healing while preventing bone infection, or osteomyelitis. The resorbable bone graft substitute is designed to remodel into healthy bone within 6-12 months, while […]
Stryker CFO Jellison retires, Boehnlein steps up | Personnel Moves
Stryker (NYSE:SYK) said yesterday that CFO and veep William Jellison is retiring, and will be replaced by former medsurg & neurotechnology group CFO Glenn Boehnlein. The Kalamazoo, Mich.-based company said Jellison, who’s been with Styker for 3 years, will pursue positions on boards and devote more time to his family. Jellison will stay on through […]